Arizona State Retirement System Sells 46,030 Shares of Zoetis Inc (ZTS)  Donna Armstrong | Aug 17th, 2018
Arizona State Retirement System cut its holdings in shares of Zoetis Inc (NYSE:ZTS) by 21.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 165,546 shares of the company's stock after selling 46,030 shares during the quarter. Arizona State Retirement System's holdings in Zoetis were worth $14,103,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. BlackRock Inc. raised its position in Zoetis by 6.7% during the 1st quarter. BlackRock Inc. now owns 41,069,741 shares of the company's stock worth $3,429,736,000 after buying an additional 2,584,199 shares during the last quarter. Polen Capital Management LLC grew its stake in shares of Zoetis by 125.3% during the 1st quarter. Polen Capital Management LLC now owns 8,943,633 shares of the company's stock worth $746,883,000 after purchasing an additional 4,974,081 shares during the period. Brown Advisory Inc. grew its stake in shares of Zoetis by 0.3% during the 1st quarter. Brown Advisory Inc. now owns 7,226,660 shares of the company's stock worth $603,499,000 after purchasing an additional 19,546 shares during the period. Wells Fargo & Company MN grew its stake in shares of Zoetis by 9.1% during the 2nd quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company's stock worth $543,099,000 after purchasing an additional 529,666 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Zoetis by 1.4% during the 1st quarter. Northern Trust Corp now owns 5,948,527 shares of the company's stock worth $496,762,000 after purchasing an additional 82,183 shares during the period. 90.98% of the stock is owned by institutional investors. Get Zoetis alerts:
In related news, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $84.76, for a total value of $169,520.00. Following the sale, the insider now owns 22,023 shares of the company's stock, valued at approximately $1,866,669.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . Also, insider Catherine A. Knupp sold 46,816 shares of Zoetis stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $90.84, for a total transaction of $4,252,765.44. Following the completion of the sale, the insider now directly owns 81,640 shares in the company, valued at approximately $7,416,177.60. The disclosure for this sale can be found here . Insiders sold a total of 197,099 shares of company stock worth $17,978,939 in the last three months. 0.35% of the stock is owned by corporate insiders.
ZTS has been the topic of a number of analyst reports. Citigroup reaffirmed a "buy" rating and set a $98.00 price objective (up previously from $85.00) on shares of Zoetis in a research note on Thursday, April 19th. Hilliard Lyons cut shares of Zoetis to a "neutral" rating in a research note on Thursday, April 19th. They noted that the move was a valuation call. Cantor Fitzgerald set a $90.00 price objective on shares of Zoetis and gave the stock a "buy" rating in a research note on Tuesday, April 24th. Craig Hallum reaffirmed a "buy" rating and set a $94.00 price objective (up previously from $87.00) on shares of Zoetis in a research note on Wednesday, April 25th. Finally, BMO Capital Markets reaffirmed a "hold" rating and set a $80.00 price objective on shares of Zoetis in a research note on Wednesday, May 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of "Buy" and a consensus price target of $90.53.
Zoetis stock opened at $91.54 on Friday. Zoetis Inc has a 1 year low of $60.44 and a 1 year high of $93.67. The firm has a market capitalization of $44.18 billion, a P/E ratio of 37.91, a P/E/G ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The firm had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.38 billion. During the same quarter last year, the company earned $0.53 EPS. The firm's revenue for the quarter was up 11.5% compared to the same quarter last year. analysts forecast that Zoetis Inc will post 3.07 EPS for the current year.
Zoetis Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What are CEFs?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS). Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter . Ã‚